Enterprise Therapeutics appoints Dr Renu Gupta as CMO

UK-based respiratory drug developer Enterprise Therapeutics has appointed Dr Renu Gupta as chief medical officer (CMO).

Dr Gupta is a physician-scientist and industry leader, with more than 20 years of experience as a CMO, most recently at Promedior, a member of the Swiss Roche (ROG: SIX) group. During a career spanning over 30 years in the biopharmaceutical industry, she has held various roles within research and development, executive management, and as a board member, including at Global Bio-Pharma, Corbus Pharmaceuticals, Breath Therapeutics, Insmed (Nasdaq: INSM), Novartis (NOVN: VX) and Bristol-Myers Squibb (NYSE: BMY).

Dr Gupta has been instrumental in implementing innovative clinical and regulatory strategies and development pathways to advance targets, including for rare disease indications, forming productive private-public sector partnerships, raising capital, and ultimately advancing molecules from drug discovery through approvals in the major global markets, noted Enterprise chief executive John Ford.